CXCR2 and neoplasm: The inhibition of CXCR2 using AZD5069 attenuated MDSC-mediated castration resistance and extended the anti-tumour effect of enzalutamide [150], which has also been investigated through the Phase 1/2 ACE trial (see Section 5.4).